adis drug evaluation

drugs 2009; 69 (16): 2257-2278
0012-6667/09/0016-2257/$55.55/0

Âª 2009 adis data information bv. all rights reserved.

 xxxd2834xxx 
in the prevention of nausea and vomiting
lily p.h. yang and lesley j. scott
adis, a wolters kluwer business, auckland, new zealand
various sections of the manuscript reviewed by:
g. adiga, department of hematology and medical oncology, montefiore medical center, bronx, new york,
usa; c.n. andrews, department of gastroenterology, university of calgary, calgary, alberta, canada;
c.c. apfel, department of anesthesia and perioperative care, university of california san francisco, san
francisco, california, usa; a.b. benson iii, feinberg school of medicine, robert h. lurie comprehensive
cancer center, northwestern university, chicago, illinois, usa; l. bergmann, department of internal
medicine ii, johann wolfgang goethe-university, frankfurt, germany; a. chan, department of pharmacy,
national university of singapore, singapore; k. charalabopoulos, department of physiology, university of
ioannina, ioannina, greece; a.l. kovac, department of anesthesiology, university of kansas medical
center, kansas city, kansas, usa; j.b. leslie, department of anesthesiology, mayo clinic college of
medicine, scottsdale, arizona, usa; k. leslie, department of anaesthesia, royal melbourne hospital,
melbourne, victoria, australia; m. marchetti, hematology unit, hospital cardinal massaia, asti, italy;
m. vergo, feinberg school of medicine, robert h. lurie comprehensive cancer center, northwestern
university, chicago, illinois, usa.
data selection
sources: medical literature published in any language since 1980 on â€˜ xxxd2834xxx â€™, identified using medline and embase,
supplemented by adisbase (a proprietary database). additional references were identified from the reference lists of published articles.
bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
search strategy: medline, embase and adisbase search term was â€˜ xxxd2834xxx â€™. searches were last updated 23 september 2009.
selection: studies in patients who received  xxxd2834xxx . inclusion of studies was based mainly on the methods section of the trials.
when available, large, well controlled trials with appropriate statistical methodology were preferred. relevant pharmacodynamic and
pharmacokinetic data are also included.
index terms:  xxxd2834xxx , chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, pharmacodynamics,
pharmacoeconomics, pharmacokinetics, therapeutic use, tolerability.

contents
summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2. pharmacodynamic properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. pharmacokinetic properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1 absorption and distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2 metabolism and excretion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3 special patient populations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.4 potential drug interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. therapeutic efficacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1 chemotherapy-induced nausea and vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.1 in patients receiving moderately emetogenic chemotherapy . . . . . . . . . . . . . . . . . . . . .
4.1.2 in patients receiving highly emetogenic chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.3 in subpopulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2258
2259
2260
2261
2261
2262
2262
2262
2263
2263
2264
2266
2267

yang & scott

2258

5.
6.
7.
8.

4.1.4 meta-analysis and postmarketing surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2 postoperative nausea and vomiting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
pharmacoeconomic considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.1 chemotherapy-induced nausea and vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.2 postoperative nausea and vomiting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dosage and administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
place of  xxxd2834xxx  in the prevention of nausea and vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2267
2268
2269
2270
2270
2271
2272
2272

summary
abstract

 xxxd2834xxx  is a second-generation serotonin  xxxg1116xxx  antagonist, with a
distinct pharmacological profile that differs from first-generation  xxxg1116xxx 
antagonists. intravenous  xxxd2834xxx  is widely indicated for the prevention of
chemotherapy-induced nausea and vomiting (cinv) in the acute and delayed
phases following moderately emetogenic chemotherapy (mec) and the prevention of cinv in the acute phase following highly emetogenic chemotherapy
(hec). in the us, oral  xxxd2834xxx  is approved for the prevention of cinv in
the acute phase following mec (although this formulation is not currently
available), and intravenous  xxxd2834xxx  is indicated for the prevention of postoperative nausea and vomiting (ponv) in the first 24 hours following surgery. all
indications are currently limited to adult patients.
intravenous  xxxd2834xxx  was noninferior to intravenous ondansetron (with
statistically greater efficacy than ondansetron) or  xxxd1924xxx  in preventing cinv
following mec, or to intravenous ondansetron or granisetron in preventing
cinv following hec, in the acute phase. statistically greater efficacy was seen
with intravenous  xxxd2834xxx  than ondansetron or  xxxd1924xxx  in preventing
cinv following mec in the delayed phase. oral  xxxd2834xxx  was noninferior to
intravenous  xxxd2834xxx  in preventing cinv in the acute phase in patients receiving mec. intravenous  xxxd2834xxx  was superior to placebo in preventing
ponv in the first 24 hours following surgery.  xxxd2834xxx  was generally well
tolerated in clinical trials. intravenous  xxxd2834xxx  is a valuable option in the
prevention of acute- and delayed-phase cinv in adult patients receiving mec,
and of acute-phase cinv in patients receiving hec. oral  xxxd2834xxx  is likely
to be a useful addition to oral formulations of other  xxxg1116xxx  antagonists in
preventing cinv in patients receiving mec. intravenous  xxxd2834xxx  is a useful
alternative to currently recommended agents in ponv prevention.

pharmacological
properties

although all  xxxg1116xxx  antagonists prevent nausea and vomiting by selective
inhibition of 5-ht3 receptors,  xxxd2834xxx  is structurally different to, and has a
higher affinity for the  xxxg1116xxx  than, the other  xxxg1116xxx  antagonists;
it is the only allosteric antagonist and has a long duration of action.  xxxd2834xxx 
has no clinically relevant effects on the cardiovascular system, including prolongation of the corrected qt interval.
the pharmacokinetic profile of intravenous  xxxd2834xxx  is generally similar
between patients receiving chemotherapy and those undergoing surgery. oral
 xxxd2834xxx  has a bioavailability of 97%.  xxxd2834xxx  is extensively distributed
and is Â»62% bound to plasma proteins. cytochrome p450 (cyp) accounts for
Â»50% of  xxxd2834xxx  metabolism, mainly by cyp2d6, cyp3a4 and cyp1a2;

Âª 2009 adis data information bv. all rights reserved.

drugs 2009; 69 (16)

 xxxd2834xxx : a review

2259

the major metabolites have minimal antagonistic activity (<1%) at the 5-ht3
receptor.  xxxd2834xxx  has a long terminal elimination half-life (mean Â»40 hours)
and is excreted mainly through the urinary route. dose adjustment of  xxxd2834xxx  is not needed on the basis of age, sex, race, renal or hepatic impairment,
concurrent medication or clinical chemistry.
therapeutic efficacy

in randomized, double-blind, multicentre trials, intravenous  xxxd2834xxx  was
noninferior to intravenous ondansetron or  xxxd1924xxx  in preventing cinv in the
acute phase in patients receiving mec, with statistically better efficacy than
ondansetron or  xxxd1924xxx  in subsequent superiority analyses in the acute and
delayed phases. intravenous  xxxd2834xxx  was noninferior to intravenous ondansetron or granisetron in preventing cinv in the acute phase following hec.
intravenous  xxxd2834xxx  in combination with dexamethasone with or without
 xxxd203xxx  was an effective cinv prophylactic regimen. oral  xxxd2834xxx  was
noninferior to intravenous  xxxd2834xxx  in preventing cinv in the acute phase in
patients receiving mec in another trial. intravenous  xxxd2834xxx  was generally
associated with better health-related quality-of-life outcomes compared with
intravenous ondansetron or  xxxd1924xxx  in patients receiving mec, or with
intravenous ondansetron in patients receiving hec. superior efficacy of intravenous  xxxd2834xxx  over placebo in preventing ponv in the 0â€“24 hour time
period was established in two other trials.

pharmacoeconomic
considerations

cost analyses modelled on two european hospital perspectives in patients receiving mec or hec suggested pharmacoeconomic benefits associated with the
use of  xxxd2834xxx  compared with that of ondansetron or first-generation 5-ht3
receptor antagonists in the management of cinv. a large us observational
study (in patients receiving various chemotherapy regimens) reported a more
favourable financial impact following the use of  xxxd2834xxx  compared with that
of ondansetron for preventing cinv.

tolerability

in clinical trials, the intravenous and oral formulations of  xxxd2834xxx  were
generally well tolerated in patients receiving chemotherapy, and intravenous
 xxxd2834xxx  was generally well tolerated in surgical patients. the incidence of
reported adverse events was low (all <10%), and the majority of these were of mild
or moderate severity; no or few study withdrawals as a result of adverse events
were attributed to study medication. headache and constipation were among the
most commonly reported adverse events with the use of  xxxd2834xxx .

1. introduction
nausea and vomiting commonly follow chemotherapy or surgery, although incidences can vary
greatly (30â€“90%[1] for chemotherapy-induced
nausea and vomiting [cinv] and 10â€“79%[2] for
postoperative nausea and vomiting [ponv]). inadequately controlled cinv and ponv may be
associated with consequences such as dehydration,
malnutrition or gastrointestinal bleeding,[3] or electrolyte imbalance, aspiration of gastric contents or
Âª 2009 adis data information bv. all rights reserved.

wound dehiscence.[4] these consequences may
lead to a reduced willingness by the patient
for future treatments[3] or delay discharge from
hospital.[4] importantly, cinv and ponv are
consistently among the most distressing effects
of chemotherapy[5] or surgery[6] as ranked by
patients.
peripheral (the enterochromaffin cells of the gastrointestinal mucosa) and central (e.g. the chemoreceptor trigger zone in area postrema of the fourth
ventricle, the vomiting centre in the formatio
drugs 2009; 69 (16)

yang & scott

2260

table i. summary of pharmacodynamic properties of  xxxd2834xxx  (pal)
mechanism of action
binds serotonin  xxxg1116xxx  selectively (pki 10.45 vs <6 for other receptors including serotonin 5-ht1a, 5-ht2a and dopamine d1)[20]
inhibits  xxxg1116xxx  function by inhibiting serotonin-dependent ca2+ influx in vitro (63% inhibition with pal** vs 21% with gra* and 11% with
ond)[17]
has higher affinity for binding sites in neural cells than other 5-ht3 ras (pki 10.1 vs 8.2â€“8.9 for ond, gra and tro)[20]
effects of serotonergic receptor antagonism
prevents cis-induced emesis (2- and 13-fold more potent than gra and ond in ferrets; Â»30-fold more potent than ond in dogs)[18]
effective prophylaxis for chemotherapy-induced (section 4.1) or postoperative (section 4.2) nausea and vomiting in clinical trials
cardiovascular effects
dose-dependently inhibits serotonin-induced,  xxxg1116xxx -mediated bradycardia as assessed by the von bezold-jarisch reflex in
anaesthetized rats (intravenous pal was 3- and 55-fold more potent than intravenous gra and ond, respectively)[18]
not associated with prolonged qtci interval in a â€˜thorough qt/qtcâ€™ study in healthy volunteers[21] (section 2) or patients (section 6), or other
cardiac adverse events in patients (section 6)
5-ht3 ras = serotonin  xxxg1116xxx  antagonists; cis = cisplatin; gra = granisetron; ond = ondansetron; pki = inhibition constant;
qtci = individually corrected qt; tro =  xxxd3451xxx . * p < 0.05, ** p < 0.001 vs control.

reticularis) pathways involving several receptor
types (e.g. serotonin 5-ht3, dopamine d2, histamine h2, a2-adrenergic, neurokinin1 and gaba)
are implicated in the initiation of the vomiting reflex
in cinv[1,7] and ponv.[8] because many receptors
are involved in the neurotransmission of nausea and
vomiting signals, the recommended preventative
strategies involve a combination of drugs with different mechanisms of action (section 8).
despite the many available agents and their
widespread use, some patients still experience
cinv[9] or ponv.[10] intravenous  xxxd2834xxx 
( xxxd2834xxx ), a second-generation  xxxg1116xxx 
antagonist, was initially approved in 2003 for the
prevention of acute- or delayed-phase cinv
following moderately emetogenic chemotherapy
(mec) or acute-phase cinv following highly
emetogenic chemotherapy (hec);[11,12] it is now
also indicated for the prevention of ponv in the
first 24 hours in the us.[13] in addition, an oral
formulation of  xxxd2834xxx  has recently (2008)
received us approval for acute-phase cinv
prophylaxis following mec, although it is not
currently available.[14]

2. pharmacodynamic properties
the pharmacodynamic properties of  xxxd2834xxx  have been reviewed previously;[12,15,16]
therefore, only a brief summary is provided here,
based on studies,[17-21] a review,[1] the us[13,14] and
eu[22] prescribing information and the european
medicines agency (emea) scientific document.[23]
 xxxd2834xxx  is a highly selective  xxxg1116xxx 
antagonist with distinct pharmacodynamic properties (table i). unlike other  xxxg1116xxx  antagonists (e.g. ondansetron,  xxxd1924xxx , granisetron) that
resemble serotonin structurally,[1] the structure of
 xxxd2834xxx  is based on a fused tricyclic ring with
an attached quinucleidine moiety (figure 1).[17] interestingly,  xxxd2834xxx  was shown to be an allosteric antagonist of the  xxxg1116xxx  and displays
positive cooperativity, whereas granisetron and ondansetron are competitive antagonists and exhibit
simple bimolecular binding.[17] competitive antagonists of serotonin compete directly with serotonin
at the same binding sites, but allosteric binding
n
o
n

this review examines the pharmacological
properties, therapeutic efficacy, pharmacoeconomics and tolerability of  xxxd2834xxx  in cancer
or surgical patients as prophylactic therapy
against nausea and vomiting.
Âª 2009 adis data information bv. all rights reserved.

h
h

â€¢ hci

fig. 1.  xxxd2834xxx  hydrochloride.

drugs 2009; 69 (16)

 xxxd2834xxx : a review

2261

(i.e. binding at a different site compared to serotonin) creates a conformational change in the
serotonin receptor so that serotonin binding is indirectly inhibited.[16] in addition,  xxxd2834xxx 
exhibits a higher affinity for 5-ht3 receptors than
other  xxxg1116xxx  antagonists (table i). it has a
long duration of action (7 hours with oral  xxxd2834xxx  vs 4 hours with an equally effective dose
of oral ondansetron in dogs following administration of cisplatin[18]), which is attributed to its
long plasma elimination half-life (section 3). preliminary in vitro data suggest that  xxxd2834xxx 
may cause receptor internalization, which may
also account for its long duration of action.[17] the
differential binding properties and long duration
of action of  xxxd2834xxx  may explain its improved efficacy versus  xxxd1924xxx  or ondansetron
in preventing delayed-phase cinv in patients receiving mec (section 4.1.1).
preliminary data from 35 patients with cancer
who received intravenous  xxxd2834xxx  0.25 mg and
dexamethasone 20 mg 30 minutes prior to hec indicate a beneficial effect, as cinv prophylaxis with
 xxxd2834xxx  and dexamethasone was associated
with an increase in caloric food intake.[19]
although supratherapeutic doses of  xxxd2834xxx  have the potential to block ion channels
involved in ventricular de- and repolarization and to prolong action potential duration in
preclinical studies,[22,23] intravenous  xxxd2834xxx  was not associated with individually
corrected qt (qtci) interval prolongation

in a â€˜thorough qt/qtcâ€™ study,[21] in accordance
with international conference on harmonisation
e14 guidelines.[24] in this study,[21] the change
in qtci interval was -3.6 msec with  xxxd2834xxx 
0.25 mg, -2.9 msec with  xxxd2834xxx  0.50 mg
and -1.5 msec with  xxxd2834xxx  2.25 mg, compared with -4.1 msec with placebo and 1.8 msec
with the active comparator moxifloxacin
(n = 42â€“46 per group).
3. pharmacokinetic properties
the pharmacokinetic properties of  xxxd2834xxx  discussed in this section are based on clinical
studies,[25-30] a review,[1] the manufacturerâ€™s prescribing information[13,14,22] and the emea scientific discussion document.[23]
the pharmacokinetics of a single dose of  xxxd2834xxx  1 or 3 mg/kg are presented in table ii;
these doses are equivalent to the recommended
doses of 0.075 mg for ponv and 0.25 mg for
cinv (section 7). the pharmacokinetic profile of
intravenous  xxxd2834xxx  is generally similar between patients receiving chemotherapy and those
undergoing surgery.[13]
3.1 absorption and distribution

bioavailability of oral  xxxd2834xxx  is 97%.[14]
intravenous  xxxd2834xxx  demonstrated a linear increase in maximum plasma concentration and area
under the concentration-time curve from time zero

table ii. key pharmacokinetic properties for recommended doses of  xxxd2834xxx  (pal). all data are mean values after a single dose
study

no. in group

dosea

cmax (ng/ml)

tmax (h)

aucÂ¥ (ng  h/ml)

tÂ½ (h)

cl (ml/min/kg)

vd (l/kg)

intravenous pal
in patients receiving chemotherapy[23,30] or in surgical patients[23]
eisenberg et al.[23,30]

6

3 mg/kg

5.63

0.144

35.8

study 2500[23]

5

1 mg/kg

1.87

0.033

21.3

6

1 mg/kg

0.35

0.5 mg

0.93

56.4
110

1.66

7.91

1.07

6.68

1.89

5.31

in healthy volunteers
stoltz et al.[25]

9.35

33.7

oral pal
in patients receiving chemotherapy
unnamed[14]
a

12

5.1

49.7

48

the 3 mg/kg dose is equivalent to 0.25 mg and 1 mg/kg is equivalent to 0.075 mg.

aucÂ¥ = area under the plasma concentration-time curve from time zero to infinity; cl = clearance; cmax = maximum plasma concentration;
tÂ½ = elimination half-life; tmax = time to reach cmax; vd = volume of distribution.

Âª 2009 adis data information bv. all rights reserved.

drugs 2009; 69 (16)

yang & scott

2262

to infinity over a dose range of 0.3 to 90 mg/kg in
healthy volunteers.[14,25]
 xxxd2834xxx  is extensively distributed,[23] with a
large apparent volume of distribution (table ii). at
concentrations of 5â€“412 nmol/ml,  xxxd2834xxx  is
Â»62% bound to plasma proteins; in in vitro studies,
the binding was nonspecific and nonsaturable.[23]
repeated administration of intravenous  xxxd2834xxx  0.25 mg/day for 3 consecutive[26] or on
alternative[27] days with concomitant dexamethasone is associated with a mean accumulation
ratio of 2.1[26] and 1.4,[27] respectively.

3.2 metabolism and excretion

cytochrome p450 (cyp) n-oxidation and
monohydroxylation accounts for Â»50% of the
metabolism of  xxxd2834xxx , giving the major
metabolites m9 and m4, respectively; these metabolites contribute <1% of the  xxxg1116xxx 
antagonistic activity of  xxxd2834xxx  and are not
considered clinically significant.[23] cyp2d6 and,
to a lesser extent, cyp3a4 and cyp1a2, oxidize
 xxxd2834xxx  to m9.[23]
mean elimination half-life (tÂ½) of  xxxd2834xxx  is Â»40 hours, although this is highly variable
and in Â»10% of patients it is 100â€“300 hours;
however, this variability is not expected to affect
clinical efficacy or safety.[23] the tÂ½ of  xxxd2834xxx  is considerably longer than that of other
 xxxg1116xxx  antagonists, which generally
range between 3 and 8 hours.[1] in healthy volunteers, after a single intravenous dose of  xxxd2834xxx , total body clearance was 160 ml/h/kg[13]
or 173 ml/min[22] and renal clearance was
66.5 ml/h/kg[13] or 53 ml/min.[22]
renal excretion is the primary route of  xxxd2834xxx  clearance. following a single intravenous dose of [14c]- xxxd2834xxx  10 mg/kg, a
mean of 83.2% of the radioactivity was recovered
in the urine and 3.4% was recovered in the faeces.[28] of the dose recovered in the urine, a mean
of 39.3% was unchanged drug, 12.5% was m9
and 10.9% was m4.[28] after a single oral dose of
[14c]- xxxd2834xxx , 85â€“93% of the radioactivity
was recovered in the urine, with 5â€“8% recovered
in the faeces.[14]
Âª 2009 adis data information bv. all rights reserved.

3.3 special patient populations

the pharmacokinetic properties of  xxxd2834xxx  were not significantly affected by mild to
moderate renal impairment, and although severe
renal impairment increased systemic exposure to
 xxxd2834xxx  by Â»28%, no dose adjustment is
needed in patients with renal impairment.[13,14,22]
the clearance of  xxxd2834xxx  was not significantly different between patients with hepatic
impairment and healthy volunteers; dose adjustment is not required in these patients.[13,14,22]
age, sex, race, concurrent medication or clinical chemistry had no effect on the clearance of
 xxxd2834xxx ; the pharmacokinetics of  xxxd2834xxx  or m9 were not affected by metabolism
status (i.e. extensive vs poor metabolizers).[22,23]
3.4 potential drug interactions

although  xxxd2834xxx  demonstrated competitive inhibition of cyp1a2, cyp2d6 and
cyp3a4 in vitro, this inhibitory potential is not
considered relevant at therapeutic drug concentrations; no induction of cytochrome p450
isoenzymes was observed with clinically relevant
concentrations of  xxxd2834xxx  in vitro.[22,23]
coadministration of cyp2d6 inducers (dexamethasone, rifampicin [rifampin]) or inhibitors (including amiodarone, chlorpromazine,
fluoxetine, haloperidol, metoclopramide) with
 xxxd2834xxx  had no significant effect on the
clearance of  xxxd2834xxx .[13,14,22,23]
no significant interactions or inhibition of antitumour activity were observed following intraperitoneal injections of  xxxd2834xxx  with cisplatin,
cyclophosphamide,  xxxd1790xxx , doxorubicin or  xxxd2655xxx  c in mice.[13,14,22,23] in clinical trials (section 4),
 xxxd2834xxx  has been safely coadministered with
analgesics, anticholinergic agents, antiemetics, antinauseants, antispasmodics or corticosteroids.[13,14,22]
coadministration of intravenous dexamethasone
20 mg[13,14] or oral  xxxd203xxx  125 mg on day 1 and
80 mg on days 2 and 3[29] with intravenous  xxxd2834xxx  0.25 mg did not affect the pharmacokinetics of
 xxxd2834xxx  in healthy volunteers (these are recommended combinations for cinv or ponv
prophylaxis [section 8]).
drugs 2009; 69 (16)

 xxxd2834xxx : a review

4. therapeutic efficacy
the efficacy of intravenous  xxxd2834xxx  in
the prevention of cinv[31-35] (section 4.1) or
ponv[36-38] (section 4.2) has been evaluated in
several randomized, double-blind, multicentre
trials in adult patients (aged â€¡18 years); the discussion in this section focuses on these trials and
is limited to treatment arms that used the recommended doses (section 7) of  xxxd2834xxx .
one of these trials[35] utilized a double-dummy
design to evaluate the oral versus the intravenous
formulation of  xxxd2834xxx  in the prevention of
cinv in patients receiving mec (section 4.1.1).
supporting data from other trials,[39-42] a metaanalysis,[43] postmarketing experience[44] and additional analyses[45] of  xxxd2834xxx  as cinv
prophylaxis are briefly discussed (section 4.1).
health-related quality-of-life (hr-qol) data
from clinical trials are discussed in sections
4.1 and 4.2.
antiemetic rescue medication was permitted.[31-38] where reported,[31,33-38] there were
no significant differences between the study
groups in terms of baseline patient characteristics
within each trial.
4.1 chemotherapy-induced nausea
and vomiting

in the pivotal cinv prevention trials, enrolled
patients had a karnofsky index (a functional
impairment scale; 100% indicates perfect health
and 0% indicates death) â€¡50%[31-33] or â€¡70%.[34]
both chemotherapy-naive or -experienced patients were included, although chemotherapyexperienced patients were excluded if they had
previously experienced greater than mild cinv.
inclusion of patients with hepatic, renal or cardiovascular impairment was at the discretion of
the investigator. patients were excluded if they:
had received or were scheduled to receive any
investigational drugs (including  xxxd2834xxx ) in
the previous 30 days; had received drugs with
potential antiemetic properties in the previous
24 hours or up to day 5 of the trial; were experiencing emesis or retching; had grade 2 or 3 nausea
according to the national cancer institute
Âª 2009 adis data information bv. all rights reserved.

2263

common toxicity criteria in the 24 hours prior
to receiving chemotherapy; or had a baseline qtc
interval >500 msec.[31-34] inclusion and exclusion
criteria were not reported for the trial that evaluated oral  xxxd2834xxx  (available as abstract
and poster).[35]
patients received  xxxd2834xxx  0.25[31-34] or
0.75 mg,[31-33]  xxxd1924xxx  100 mg[31] or granisetron 3 mg[34] as a single intravenous bolus infused
over 30 seconds, or ondansetron 32 mg[32,33] as a
single intravenous bolus infused over 15 minutes,
30 minutes prior to chemotherapy.[35] in one
trial,[35] oral  xxxd2834xxx  was given as a single
dose of 0.25, 0.50 or 0.75 mg 1 hour prior to
chemotherapy.[14] a single dose of concomitant
intravenous dexamethasone 20 mg, administered
15 minutes prior to chemotherapy, was permitted
at the investigatorâ€™s discretion in some
trials.[31,33,35] the lowest  xxxd2834xxx  dose
(0.25 mg) employed in these trials was established
as the minimum effective dose in a randomized,
double-blind, dose-ranging trial,[30] which utilized an equivalent dose (3 mg/kg). the regimens
in the trials[39,40] that utilized  xxxd2834xxx  in
combination with dexamethasone and  xxxd203xxx 
for cinv prophylaxis (as recommended by
treatment guidelines [see section 8]) are discussed
in sections 4.1.1 and 4.1.2.
the primary efficacy endpoint in the cinv
prevention trials[31-35] was the rate of complete
response (cr) [defined as no emetic episode
and no use of rescue medication] in the first
24 hours (i.e. the acute phase) following chemotherapy in the intent-to-treat population (i.e.
all randomized patients who received chemotherapy and study medication). noninferiority of
intravenous  xxxd2834xxx  relative to the comparator was achieved if the lower boundary of the
97.5% confidence interval (ci) for the betweengroup difference was greater than -15%,[31-33] or
if the lower boundary of the 95% ci for the
between-group difference was >10%.[34] oral  xxxd2834xxx  was noninferior to intravenous  xxxd2834xxx  if the lower boundary of the 98.3% ci
for the between-group difference was greater
than -15%.[14,35]
the effect of  xxxd2834xxx  as cinv prophylaxis
on hr-qol was examined in three trials,[31-33] using
drugs 2009; 69 (16)

yang & scott

2264

table iii. clinical efficacy of intravenous (iv)  xxxd2834xxx  (pal) in patients (pts) receiving moderately or highly emetogenic chemotherapy.
data obtained from the intent-to-treat population of randomized, double-blind, multicentre, phase ii[34] or iii[31-33] noninferiority trials. all study
medications were administered as a single iv bolus infused over 30 seconds at 30 minutes prior to chemotherapy, unless otherwise stated;
data from treatment arms of nonapproved pal doses are not presented. rescue medication was permitted in all trials
study

regimen (mg)

no. of pts

complete responsea (% of pts)
0â€“24 h

c

complete controlb (% of pts)

24â€“120 h

0â€“120 h

0â€“24 h

24â€“120 h

0â€“120 h

in pts receiving moderately emetogenic chemotherapy
eisenberg et al.[31]d

gralla et al.[32]

pal 0.25 â€“ dex 20e

189

63.0*

54.0**

46.0*

48.1*

41.8*

dol 100 â€“ dex 20e

191

52.9

38.7

34.0

36.1

30.9

[-1.7, 21.9]f ni

[3.4, 27.1]f

[0.3, 23.7]f

74.1***

69.3***

66.7***g

63.0***g

50.3

44.9

pal 0.25

189

81.0**

h

185

68.6

55.1

50.3

[1.8, 22.8]f ni/s

[7.5, 30.3]f

[7.4, 30.7]f

ond 32

in pts receiving highly emetogenic chemotherapy
aapro et al.[33]

yu et al.[34]

pal 0.25 â€“ dex 20e

223

59.2

45.3

40.8

56.5

ond 32h â€“ dex 20e

221

57.0

38.9

33.0

51.6

[-8.8, 13.1]f ni

[-4.6, 17.3]f

[-2.9, 18.5]f

50.0â€“74.0i

pal 0.25

104

82.7

gra 3

104

72.1

48.1â€“62.5i

10.6 [1.11, Â¥] ni
f

a

defined as no emetic episode and no use of rescue medication. noninferiority of iv pal relative to the comparator was established if the
lower boundary of the 95% confidence interval (ci) of the between-group difference was >10%[34] or that of the 97.5% cl was greater than
-15%.[31-33]

b

defined as no emetic episode, no use of rescue medication and no more than mild nausea.

c

primary efficacy endpoint (i.e. the acute phase).

d

the prespecified, one-sided, statistical significance level for this trial was p < 0.0125.

e

concomitant iv dex (or oral dex 20 mg or iv methylprednisolone 125 mg in one trial[31]) 15 minutes prior to chemotherapy, at the
physicianâ€™s discretion; Â»5%[31] or 67.0%[33] of pts received corticosteroids.

f

97.5%[31-33] or 95%[34] ci of the between-group difference. the between-group difference was not reported in some trials.[31-33]

g

pooled data of pal 0.25 mg and pal 0.75 mg (n = 189) groups.

h

infused over 15 minutes.

i

range of individual timepoints within this phase (i.e. delayed phase).

dex = dexamethasone; dol =  xxxd1924xxx ; gra = granisetron; ni = noninferior efficacy relative to comparator; ni/s = noninferior efficacy
relative to comparator, with statistically better efficacy than comparator in superiority analysis; ond = ondansetron. * p < 0.05, ** p Â£ 0.01,
***
p Â£ 0.001 vs comparator.

the functional living index â€“ emesis (flie; a
validated instrument[46,47]).
4.1.1 in patients receiving moderately
emetogenic chemotherapy
comparison with ondansetron

intravenous  xxxd2834xxx  0.25 mg was shown to
be noninferior to intravenous ondansetron 32 mg in
the prevention of cinv associated with mec, with
subsequent statistical analysis showing that  xxxd2834xxx  had greater efficacy than ondansetron in
Âª 2009 adis data information bv. all rights reserved.

terms of the cr rate, in the acute phase (primary endpoint; table iii).[32]  xxxd2834xxx  generally provided greater prophylactic efficacy than
ondansetron, in the delayed and overall phases
as assessed by cr and complete control (cc)
rates (table iii) [cc is defined as no emetic episode, no need for rescue medication and no
more than mild nausea]. in addition, relative to
ondansetron,  xxxd2834xxx  prophylaxis was associated with a significantly (p = 0.0003) prolonged time to treatment failure (i.e. time to
first emetic episode or use of rescue medication,
drugs 2009; 69 (16)

 xxxd2834xxx : a review

whichever occurred first) by kaplan-meier analysis. significantly (p Â£ 0.05) more  xxxd2834xxx 
than ondansetron recipients were free of emetic
episodes in the acute (85% vs 71%), delayed (80%
vs 61%) and overall (75% vs 55%) phases (all values estimated from a graph). the number of
emetic episodes was significantly (p Â£ 0.05) lower
in the  xxxd2834xxx  than ondansetron group in
all three phases (numerical data not reported).[32]
comparison with  xxxd1924xxx 

in patients receiving mec, intravenous  xxxd2834xxx  0.25 mg was noninferior relative to intravenous  xxxd1924xxx  100 mg in preventing cinv
as assessed by the cr rate in the acute phase
(primary endpoint; table iii).[31] the cr rate was
significantly higher with  xxxd2834xxx  than with
 xxxd1924xxx  in the delayed and overall phases
(table iii). in addition, the cc rate was significantly higher with  xxxd2834xxx  than  xxxd1924xxx 
in the delayed and overall phases (table iii).  xxxd2834xxx  was associated with fewer emetic episodes (p Â£ 0.0183) in all phases, more patients
with no emetic episodes (p Â£ 0.028) in the delayed
and overall phases, and more patients with
no nausea on days 2 and 3 (p < 0.05) than  xxxd1924xxx  (numerical data not reported). the median
time to first emetic episode (>120 vs 41.5 hours)
and median time to treatment failure (51.1 vs
24.6 hours) was higher with  xxxd2834xxx  than
with  xxxd1924xxx  (all p < 0.05).[31]
health-related quality of life

intravenous  xxxd2834xxx  0.25 mg was generally associated with better hr-qol outcomes
following mec than intravenous ondansetron
32 mg or  xxxd1924xxx  100 mg in a pooled analysis[48] of data from two trials.[31,32] more patients
receiving  xxxd2834xxx  (n = 378) than those receiving ondansetron or  xxxd1924xxx  (combined
n = 376) experienced â€˜no impact of cinv on daily
lifeâ€™ (nidl) in the acute-phase nausea (66% vs
58%), vomiting (80% vs 72%) and total (72% vs
64%) domains, and the delayed-phase nausea
(65% vs 54%), vomiting (79% vs 70%) and total
(70% vs 58%) domains (all p < 0.01). a significant
(p < 0.05) difference between  xxxd2834xxx  and
ondansetron or  xxxd1924xxx  was observed for the
number of patients experiencing nidl in 9 of
Âª 2009 adis data information bv. all rights reserved.

2265

18 acute phase and in 17 of 18 delayed phase individual flie items.
triple prophylactic regimen

the efficacy of  xxxd2834xxx  plus dexamethasone and  xxxd203xxx  as cinv prophylaxis
was evaluated in an open-label, multicentre trial
in 58 patients receiving mec.[39] in this trial,
patients received intravenous  xxxd2834xxx 
0.25 mg 30 minutes prior to chemotherapy on day
1, oral dexamethasone 12 mg 1 hour prior to
chemotherapy on day 1 and 8 mg on days 2 and 3,
and oral  xxxd203xxx  125 mg 1 hour prior to chemotherapy on day 1 and 80 mg on days 2 and 3.
intravenous  xxxd2834xxx  in combination
with oral dexamethasone and oral  xxxd203xxx 
was an effective cinv prophylactic regimen in
patients receiving mec in this open-label trial.[39]
the cr rate was 88% (acute phase) and 78%
(delayed and overall phases), with >90% of patients experiencing no emetic episode at any
timepoint.[39]
oral versus intravenous  xxxd2834xxx 

the efficacy of oral  xxxd2834xxx  0.50 mg was
noninferior to that of intravenous  xxxd2834xxx 
0.25 mg in preventing acute-phase cinv as assessed by cr rate in patients receiving mec[35]
(primary endpoint; figure 2). however, noninferiority between the oral and intravenous formulations of  xxxd2834xxx  was  xxxd3237xxx 
for the delayed and overall phases (figure 2). post
hoc equivalence was shown in terms of the number of patients not experiencing emesis in the
acute (82.5% vs 77.2%), delayed (73.8% vs 74.7%)
and overall (70.6% vs 67.3%) phases, and the
proportion of patients without nausea in the
acute (58.8% vs 57.4%), delayed (49.4% vs 47.5%)
and overall (45.6% vs 42.6%) phases (all p < 0.05,
the significance limit for the equivalence test of
proportions).[35] the majority of patients in any
treatment arm (79â€“97%) experienced no or mild
grade nausea.[35]
the addition of dexamethasone to cinv prophylaxis with  xxxd2834xxx  increased the cr rate in
the acute phase by Â»10â€“20%.[35] half of the patients
in this trial received concomitant dexamethasone
8 mg and the other half received placebo. subgroup
analysis of data from patients receiving concomitant
drugs 2009; 69 (16)

yang & scott

2266

pal 0.5 mg po (n = 160)
pal 0.25 mg iv (n = 162)

complete response (% of pts)

90
80

59%
(âˆ’6.5, 18.2)

70

âˆ’2.9%
(âˆ’16.3, 10.5)

60
50
40
30
20
10
0
acute phase
(0âˆ’24 h)

delayed phase
(24âˆ’120 h)

overall phase
(0âˆ’120 h)

fig. 2. comparative efficacy of oral (po) versus intravenous (iv)
 xxxd2834xxx  (pal) as prophylaxis against chemotherapy-induced
nausea and vomiting. complete response (defined as no emetic
episode and no use of rescue medication in the first 24 hours) in the
intent-to-treat population of a randomized, double-blind, doubledummy, multicentre, noninferiority trial in adult patients (pts) receiving moderately emetogenic chemotherapy.[35] po or iv pal (infused
over 30 seconds) was administered 1 hour or 30 minutes prior to
chemotherapy; rescue medication was permitted. data from nonapproved pal doses are not presented. numbers above the bars
indicate the between-group difference and numbers in parentheses
indicate the 98.3% confidence interval (ci), obtained from the us
prescribing information (data for the overall phase were not reported);[14] noninferiority of po pal relative to iv pal was established if the lower boundary of the 98.3% ci was greater than
-15%.[35]

dexamethasone reported no significant differences
in the cr rates of recipients of oral compared with
intravenous  xxxd2834xxx , with generally similar
results in terms of secondary endpoints (numerical
data not reported).[49]
patient satisfaction with antiemetic treatment
was high with both formulations of  xxxd2834xxx , with patients in all treatment groups
reporting global satisfaction (up to day 5) of
>90 mm on a 100 mm visual analogue scale.[35]
4.1.2 in patients receiving highly
emetogenic chemotherapy

assessed by the cr rate in the acute phase (primary endpoint) [table iii].[33] noninferiority of
 xxxd2834xxx  relative to ondansetron was also
established in the delayed and overall phases
(table iii). more  xxxd2834xxx  than ondansetron recipients experienced no emetic episodes in
the delayed (56.5% vs 46.6%; p = 0.0137) and
overall (51.1% vs 39.4%; p = 0.013) phases, with
the median time to first emetic episode favouring
 xxxd2834xxx  prophylaxis (>120 vs 42.7 hours;
p = 0.023). subgroup analysis of data in patients
who received concomitant intravenous dexamethasone 20 mg showed a longer time to
treatment failure in the  xxxd2834xxx  than
the ondansetron group (48.2 vs 27.4 hours;
p = 0.032); other results from this subgroup of
patients support the results reported for the
overall patient population.[33]
comparison with granisetron

intravenous  xxxd2834xxx  0.25 mg was noninferior to intravenous granisetron 3 mg in preventing cinv associated with hec in the acute
phase, as assessed by cr rate (primary endpoint;
table iii).[34] the cr rate was not significantly
different between the  xxxd2834xxx  and granisetron groups for the delayed phase (table iii).[34]
the results of two other comparative
trials[50,51] of  xxxd2834xxx  versus granisetron are
discussed in section 8.
health-related quality of life

in patients receiving hec and  xxxd2834xxx 
0.25 mg or ondansetron 32 mg for cinv prophylaxis,[33] the proportion of patients who experienced nidl in the acute phase was 74%
versus 66% (nausea domain), 81% versus 71%
(vomiting domain) and 78% versus 68% (total
domain); corresponding values for the delayed
phase were 55% versus 46%, 67% versus 66%
and 59% versus 52% (no statistical analyses
reported).
triple prophylactic regimen

comparison with ondansetron

in patients receiving hec, intravenous  xxxd2834xxx  0.25 mg was noninferior to intravenous ondansetron 32 mg (some patients received concomitant
intravenous dexamethasone) in preventing cinv as
Âª 2009 adis data information bv. all rights reserved.

a randomized, double-blind, pilot study[40] investigated the combined prophylactic efficacy of
 xxxd2834xxx , dexamethasone and  xxxd203xxx  in 71
patients receiving hec. all patients received intravenous  xxxd2834xxx  0.25 mg prior to chemotherapy
drugs 2009; 69 (16)

 xxxd2834xxx : a review

on day 1 (the exact time was not specified) and oral
dexamethasone 12 mg on day 1. in addition, patients
received oral  xxxd203xxx  125 mg on day 1 and 80 mg
on days 2 and 3 (n = 28),  xxxd203xxx  125 mg on day 1
and placebo on days 2 and 3 (n = 27), or placebo on
days 1â€“3 (n = 16).
intravenous  xxxd2834xxx  plus intravenous
dexamethasone and oral  xxxd203xxx  was an
effective combination in preventing cinv in
patients receiving hec.[40] the majority
(92.6â€“100%) of patients receiving  xxxd2834xxx 
plus dexamethasone and  xxxd203xxx  did not experience emesis in the acute, delayed and overall
phases; 50.0â€“93.8% of those receiving  xxxd2834xxx  plus dexamethasone without  xxxd203xxx 
experienced no emesis (no statistical analysis
reported).[40]
4.1.3 in subpopulations

intravenous  xxxd2834xxx  is effective in preventing cinv in elderly patients. in an openlabel trial[41] in adult patients (aged â€¡18 years)
receiving  xxxd2834xxx  0.25 mg and intravenous
dexamethasone (16 mg on day 1, 8 mg every
12 hours on days 2 and 3, and 4 mg every 12 hours
on days 4 and 5) followed by mec or hec, no
statistically significant difference in cr or cc
rates (in all phases) was observed between nonelderly (aged <65 years; n = 24) and elderly (aged
â€¡65 years; n = 23) patients. in a pooled analysis[45]
of the data from the elderly patients of two mec
trials,[31,32] a significant difference at the prespecified level of p < 0.025 in the cr rates was
demonstrated between patients receiving  xxxd2834xxx  0.25 mg (n = 79) and ondansetron 32 mg
or  xxxd1924xxx  100 mg (n = 86) in the delayed
(72.2% vs 53.5%; p = 0.016) and overall (70.9% vs
51.2%; p = 0.011) phases, but not in the acute
phase (84.8% vs 74.4%; p > 0.025).
intravenous  xxxd2834xxx  plus dexamethasone is
an effective cinv prophylactic regimen in patients
with breast cancer. in a randomized, double-blind,
multicentre trial (abstract presentation)[42] in patients who received intravenous  xxxd2834xxx 
0.25 mg 30 minutes prior plus intravenous dexamethasone 8 mg Â»1 hour prior to an anthracycline
and/or cyclophosphamide chemotherapy regimens,
noninferiority in terms of cr rates (in the acute,
Âª 2009 adis data information bv. all rights reserved.

2267

delayed and overall phases) was established (i.e. the
lower boundary of the 95% ci of the between-group
difference met the prespecified criteria of greater
than -15%) in patients who did (53.7â€“68.5%;
n = 149) or did not (53.6â€“59.5%; n = 151) receive oral
dexamethasone 4 mg twice daily on days 2 and 3.[42]
the reduced need for concomitant dexamethasone associated with  xxxd2834xxx  for
cinv prophylaxis[42] was supported by the
findings of a subgroup analysis (abstract presentation) of data from 324 patients.[52] no significant (all p > 0.05) difference was found in
the cr rates between patients who received
intravenous  xxxd2834xxx  0.25 mg and intravenous dexamethasone 8 mg only on day 1 and
those who also received oral dexamethasone 8 mg
on days 2 and 3, prior to receiving an anthracycline plus cyclophosphamide regimen (55.8% vs
60.7%) or another mec regimen (68.5% vs
72.0%).[52]
4.1.4 meta-analysis and
postmarketing surveillance

a meta-analysis (abstract presentation) of
randomized clinical trials that compared intravenous  xxxd2834xxx  0.25 mg with other
 xxxg1116xxx  antagonists indicated a favourable cinv prophylaxis outcome with  xxxd2834xxx  relative to ondansetron, granisetron and
 xxxd1924xxx .[43] in 1298 patients, acute-phase
nausea (relative risk [rr] 0.75 [95% ci 0.64, 0.88;
p = 0.004]), delayed-phase nausea (rr 0.73 [95%
ci 0.66, 0.82; p < 0.00001]), acute-phase vomiting
(rr 0.78 [95% ci 0.67, 0.90; p = 0.0008]) and
delayed-phase vomiting (rr 0.75 [95% ci 0.67,
0.84; p < 0.00001]) occurred less frequently with
 xxxd2834xxx  than ondansetron, granisetron or
 xxxd1924xxx .[43]
data from a postmarketing surveillance programme[44] conducted in the clinical practice
setting supported the prophylactic efficacy of
intravenous  xxxd2834xxx  established in clinical
trials[31-34] (sections 4.1.1 and 4.1.2). the combined cr rates in 135 patients who received
mec or hec (50% for each) and a single dose of
 xxxd2834xxx  0.25 mg were 87% (95% ci 81, 93)
for day 1 and 72% (95% ci 64, 80) for days 2â€“5
(p < 0.05 for day 1 vs 2â€“5).[44]
drugs 2009; 69 (16)

yang & scott

2268

co-primary endpoint of cr rate for the 24â€“72
hours period in two trials.[36,37] superiority of
intravenous  xxxd2834xxx  relative to placebo was
established if the between-group difference was
statistically significant at p < 0.0167 (the prespecified level of statistical significance).[36,37]
the effect of  xxxd2834xxx  as ponv prophylaxis on hr-qol was examined in one trial[36]
using the european organization for research
and treatment of cancer (eortc) qlq-c30
questionnaire; the eortc qlq-c30 questionnaire was designed for, and validated in,
patients receiving chemotherapy, not surgical
patients.[55,56]
intravenous  xxxd2834xxx  was generally superior to placebo in preventing ponv in surgical
patients (table iv). the cr rates were higher
with  xxxd2834xxx  0.075 mg or 1 mg/kg (considered equivalent doses) than with placebo in the
0â€“24 hours period (primary or co-primary endpoint) in three trials;[36-38] however, the difference
in cr rates was significant in the 24â€“72 hours
period (co-primary endpoint) in only one[37] of
two[36,37] trials (table iv).
intravenous  xxxd2834xxx  0.075 mg or 1 mg/kg
demonstrated better efficacy than placebo in
preventing ponv as assessed by some, but not
all, secondary endpoints, including the cr rate
for the 0â€“72 hours period (table iv) and the

4.2 postoperative nausea and vomiting

in two ponv prevention trials,[36,37] enrolled
patients had an american society of anesthesiologists physical status class of i to iii (i.e.
normal, healthy patient or patient with mild to
severe, but not constantly life-threatening, systemic disease)[53] and were scheduled to undergo
surgery of â€¡1 hourâ€™s duration. all patients had at
least two risk factors for ponv, including female
gender, nonsmoking status of â€¡12 months or a
history of ponv or  xxxd1892xxx . patients
receiving chemotherapy in the previous 4 weeks
or emetogenic radiotherapy in the previous
8 weeks were excluded from these trials.[36,37] inclusion and exclusion criteria were not reported
for another ponv prevention trial (abstract
presentation), although all enrolled patients were
women.[38] results for a subset of patients[54]
from this latter trial[38] are not discussed.
in the ponv prevention trials, patients received
a single intravenous bolus of  xxxd2834xxx  0.025,
0.05 or 0.075 mg,[36,37] or 0.130 mg/kg[38] (0.075 mg
and 1 mg/kg are considered equivalent doses), or
placebo, infused over 10 seconds and administered
no more than 5 minutes before the induction of
anaesthesia[36,37] or at the time of skin closure.[38]
the primary efficacy endpoint was the cr rate
for the 0â€“24 hours period in all trials,[36-38] with a

table iv. clinical efficacy of intravenous  xxxd2834xxx  (pal) in preventing postoperative nausea and vomiting in surgical patients (pts) with
an american society of anesthesiologists physical status i to iii. data obtained from two phase iii[36,37] and one phase ii[38] randomized,
double-blind, multicentre trials. patients received pal or placebo (pl) as a single intravenous bolus infused over 10 seconds, Â£5 minutes
before the induction of anaesthesia; data from nonapproved doses of pal are not presented. rescue medication was permitted in all trials
study
candiotti et al.[36]
kovac et al.[37]
white and scuderi[38]

regimen

no. of pts

complete responsea (% of pts)

no vomiting (% of pts)

0â€“24 hb

24â€“72 hc

0â€“72 h

0â€“24 h

24â€“72 h

0â€“24 h

24â€“72 h

49

39*

67

91

34*d

75d
72d

no nausea (% of pts)

pal 0.075 mg

138

43**

pl

136

26

41

24

56

91

22d

pal 0.075 mg

135

56**

70**

52*

60***

10

50***

pl

52

36

40

136

36

pal 1 mg/kge

62

44*

73*

4

pl

62

19

47

29

a

defined as no emetic episode and no use of rescue medication. superiority of pal relative to pl was established if p < 0.0167.

b

primary[38] or co-primary[36,37] endpoint.

c

co-primary endpoint.[36,37]

d

values estimated from a graph.

e

this dose is considered equivalent to pal 0.075 mg.

*

p < 0.05, ** p < 0.0167, *** p < 0.001 vs pl.

Âª 2009 adis data information bv. all rights reserved.

drugs 2009; 69 (16)

 xxxd2834xxx : a review

number of patients not experiencing vomiting or
nausea in the first 0â€“24 hours (table iv).[36,37] the
time to treatment failure (as assessed by kaplanmeier analysis) was significantly (p Â£ 0.0185)
longer in recipients of  xxxd2834xxx  0.075 mg
than in those receiving placebo.[36,37]
hr-qol outcomes in surgical patients were
generally better in those receiving  xxxd2834xxx 
than placebo for ponv prophylaxis.[36] intravenous  xxxd2834xxx  was associated with a
significantly (p Â£ 0.03) greater improvement in
patient functioning than placebo for the total
score and the appetite (57% vs 44%), social life
(73% vs 62%) and enjoyment of life (66% vs 57%)
subdomains of the eortc qlq-c30 questionnaire, but not for the sleep (73% vs 64%) or
physical activity (65% vs 59%) subdomains.[36]
5. pharmacoeconomic considerations
the pharmacoeconomics of  xxxd2834xxx 
prophylaxis have been reported in three studies.[57-59] two[57,58] of these studies analysed the
cost of managing cinv following prophylaxis
with a single dose of  xxxd2834xxx  0.25 mg from a
healthcare payerâ€™s perspective in european
countries, utilized a 5-[57] or 6-day[58] decision tree
model and obtained efficacy data from clinical
trials. one study[57] compared  xxxd2834xxx  with
intravenous ondansetron 32 mg and was based on
a hospital perspective of five european countries
(germany, italy, russia, the netherlands and
uk). the other study[58] was conducted from the
italian national health service perspective and
compared  xxxd2834xxx  with various regimens
of repeated dosages of oral or intravenous
first-generation  xxxg1116xxx  antagonists. the
third study was a large, retrospective, cost analysis in a us oncology practice setting, based
on an integrated medical records and billing
database.[59]
in a european model of patients who received
mec, the use of a single dose of intravenous  xxxd2834xxx  0.25 mg as cinv prophylaxis was estimated to have a favourable drug price ratio relative
to intravenous ondansetron 32 mg.[57]  xxxd2834xxx 
prophylaxis was estimated to reduce emetic episodes
by 2.31 and rescue medications by 0.29 units
Âª 2009 adis data information bv. all rights reserved.

2269

compared with ondansetron; therefore, to provide a
lower than or equal to net treatment cost for the
hospital, the price of  xxxd2834xxx  can be higher
than ondansetron by 1.55- to 2.60-fold, depending
on the country (where reported, 2002 or 2003 costs
were used). in sensitivity analysis,  xxxd2834xxx  remained the preferred agent in all scenarios in all five
countries (drug price ratio 1.03â€“1.23).[57]
in an italian model of patients who received
mec or hec,[58] cinv prophylaxis with intravenous  xxxd2834xxx  was cost saving relative
to intravenous and/or oral first-generation 5-ht3
receptor antagonist. the management of cinv
was predicted to cost h26 less with  xxxd2834xxx 
than a first-generation  xxxg1116xxx  antagonist (h92 vs h118) because of differences in the
cost of drug acquisition (h72 vs h93 [weighted
mean cost]) and management of emesis (h20 vs
 xxxd1544xxx ) [all 2006 values]. the favourable costs with
 xxxd2834xxx  prophylaxis reflects that only a
single dose is required compared with repeated
administration of comparator agents, and  xxxd2834xxx  had better input efficacy leading to an
estimated reduced need for the management of
emesis. in sensitivity analysis, the results were
robust to a 10% increase or decrease in key
parameters.[58]
in the retrospective us study in patients who
received various chemotherapy regimens (including mec and hec), intravenous  xxxd2834xxx  0.25 mg prophylaxis was associated with
lower costs than intravenous ondansetron 32 mg,
based on data from an integrated medical records
and billing database (2005â€“6 costs).[59] an extreme cinv event (defined as cinv requiring
medical attention) was experienced by 4.0% of
1558  xxxd2834xxx  and 12.3% of 1287 ondansetron recipients in cycle 1 (105 vs 325 extreme
cinv events were reported for cycles 2â€“6), resulting in an overall impact over a 2-year period
of 42 840 minutes in terms of management time
with  xxxd2834xxx  prophylaxis and 123 165 minutes with ondansetron prophylaxis (representing
a 2.9-fold increase).[59]
pharmacoeconomic analyses, including those of
 xxxd2834xxx , are subject to a number of limitations.
pharmacoeconomic analyses based on clinical trials
drugs 2009; 69 (16)

yang & scott

2270

pal 0.25 mg (n = 633)
ond 32 mg (n = 410)
dol 100 mg (n = 194)

18

incidence (% of pts)

16
14
12
10
8
6
4
2
0
headache

constipation

diarrhoea

dizziness

fatigue

abdominal
pain

insomnia

fig. 3. tolerability of intravenous  xxxd2834xxx  (pal) in the prevention of chemotherapy-induced nausea and vomiting in adult patients (pts).
pooled data, obtained from the us prescribing information,[13] of adverse events with an incidence â€¡2% in any treatment arm in phase iii,
randomized, double-blind, multicentre trials.[31-33] pts received pal, ondansetron (ond) or  xxxd1924xxx  (dol) intravenously 30 minutes prior to
chemotherapy (see section 4 for additional trial design details). data for the nonapproved pal dose groups are not shown.

extrapolate the results of such trials to the general
population; however, patient populations, rates
of compliance and major outcomes in clinical
trials may differ from those observed in real-life
practice. modelled analyses, such as the two[57,58]
presented in this section, rely on a number of
assumptions and use data from a variety of
sources. results of pharmacoeconomic analyses
may not be applicable to other geographical regions because of differences in healthcare systems, medical practice and unit costs. despite
these inherent limitations, currently available
studies suggest that the use of  xxxd2834xxx  as
cinv prophylaxis has pharmacoeconomic benefits relative to that with first-generation 5-ht3
receptor antagonists.

6. tolerability
the tolerability data for intravenous or oral
 xxxd2834xxx  were obtained from clinical
trials,[31-38,41] a meta-analysis[43] and a retrospective analysis[45] of data from elderly patients
(study design details are presented in section 4),
the us[13,14] and eu[22] prescribing information
and the emea scientific discussion document.[23]
discussion of data is primarily based on the recommended doses of  xxxd2834xxx  (section 7).
Âª 2009 adis data information bv. all rights reserved.

6.1 chemotherapy-induced nausea
and vomiting

intravenous  xxxd2834xxx  was generally
well tolerated in clinical trials of cinv prevention.[31-34] the majority of adverse events were
mild (64.1% of 582[31]) or mild to moderate (>90%
of 673[33]) in severity, and Â»80%[31-33] were not
considered to be related to study medication. the
most common adverse events reported with intravenous  xxxd2834xxx  in a pooled analysis[13] of
three cinv trials[31-33] are presented in figure 3.
no clinically relevant differences were reported in
terms of the incidence or duration of all or
treatment-emergent adverse events between  xxxd2834xxx  and ondansetron,[32,33]  xxxd1924xxx [31]
or granisetron.[34]
results from a meta-analysis of randomized
clinical trials did not demonstrate a significant difference in the incidence of common adverse events
associated with  xxxg1116xxx  antagonists between intravenous  xxxd2834xxx  and ondansetron,
granisetron or  xxxd1924xxx .[43] the rr of headache
(0.83), dizziness (0.40), constipation (1.35) and
diarrhoea (0.67) of  xxxd2834xxx  compared with
ondansetron, granisetron and  xxxd1924xxx  were all
statistically insignificant (all p > 0.05).[43]
intravenous  xxxd2834xxx  was generally well
tolerated by elderly patients,[45] including those
previously experiencing grade 3â€“4 cinv.[41]
drugs 2009; 69 (16)

 xxxd2834xxx : a review

few serious adverse events (<5%) were reported in clinical trials, and none were considered
related to the study medication.[31-34] no patient
deaths were considered to be related to study
medication.[31,32] where reported, no[31] or few[32]
study withdrawals as a result of adverse events
were considered to be related to study medication; one patient who received intravenous  xxxd2834xxx  0.75 mg (a higher than recommended
dose; section 7) withdrew because of debility
that was considered at least possibly related to
 xxxd2834xxx .[32]
in clinical trials, no clinically relevant difference in vital signs, ecg or laboratory tests were
observed between  xxxd2834xxx  and  xxxd1924xxx [31] or ondansetron,[32,33] or in qtc interval
prolongation between  xxxd2834xxx  and placebo.
no relevant supraventricular or ventricular arrhythmias (including torsades de pointes) or atrioventricular conduction defects were reported
with the use of  xxxd2834xxx  prophylaxis.[23]
postmarketing experience of intravenous
 xxxd2834xxx  0.25 mg in cinv prophylaxis reported mild adverse events (vertigo and dyspepsia) in 1.5% of 135 patients.[44] postmarketing
cases of hypersensitivity reactions and injectionsite reactions (including burning, discomfort
or pain) have been reported with the use of
intravenous  xxxd2834xxx  0.25 mg for cinv
prevention.[13]
oral  xxxd2834xxx  was generally well tolerated
in mec recipients. in a dose-ranging trial in
cinv prevention,[35] headache was reported in
3.7% of oral  xxxd2834xxx  0.50 mg (n = 161)
and 8.6% of intravenous  xxxd2834xxx  0.25 mg
(n = 163) recipients and constipation in 0.6%
and 3.1% of patients. all other adverse events
(e.g. fatigue, hypertension, pyrexia, myalgia or
postural dizziness) occurred at an incidence of
Â£1%.[14] the majority of adverse events were
mild in severity; no dose-dependent relationship
in the incidence of adverse events was observed
in oral  xxxd2834xxx  0.25, 0.50 or 0.75 mg
groups.[35]
Âª 2009 adis data information bv. all rights reserved.

6.2 postoperative nausea and vomiting

intravenous  xxxd2834xxx  was generally well
tolerated in adult patients receiving the drug for
ponv prevention.[37] most adverse events were
mild or moderate in severity and the incidence of
adverse events was not significantly different to
that with placebo (statistical analyses not reported).[37] the most commonly reported adverse
events in a pooled analysis[13] of three ponv
prevention trials[36-38] with  xxxd2834xxx  are
presented in figure 4.
treatment-related adverse events were reported in 7% of  xxxd2834xxx  0.075 mg (n = 138)
and 10% of placebo (n = 135) recipients.[36] unspecified severe adverse events were reported
in 4% of  xxxd2834xxx  0.075 mg (n = 135) and 5%
of placebo (n = 136) recipients.[37] no withdrawals because of serious adverse events were
reported.[36]
in ponv trials, qt interval prolongation was
among the most frequently reported adverse events
(figure 4). however, a pooled analysis[60] of all three
ponv trials[36-38] did not demonstrate a dosedependent relationship in the incidence of qtc interval prolongation, and the change from baseline was
not significantly different to that seen in the placebo
group; therefore, the reported cases of qtc interval
18
16
incidence (% of pts)

most (>80%) of the reported adverse events were
not related to study medication.[41]

2271

pal 0.075 mg or 1 mug/kg (n = 336)
pl (n = 369)

14
12
10
8
6
4
2
0
qt interval bradycardia
prolongation

headache

constipation

fig. 4. tolerability of intravenous  xxxd2834xxx  (pal) in the prevention of postoperative nausea and vomiting in adult patients (pts).
pooled data, obtained from the us prescribing information,[13] of
adverse events with an incidence â€¡2% in any treatment arm in phase
iii[36,37] or phase ii,[38] randomized, double-blind, multicentre trials.
pts received pal or placebo (pl) intravenously Â£5 minutes prior to
the induction of anaesthesia (see section 4 for additional trial design
details). data for the nonapproved pal dose groups are not shown.

drugs 2009; 69 (16)

yang & scott

2272

table v. recommended usage of intravenous  xxxd2834xxx  in chemotherapy-induced nausea and vomiting (cinv) and postoperative
nausea and vomiting (ponv) in adult patients, based on us[13] and eu[22] prescribing information
indication

phase

recommended dose and administration

cinv (mec)[13,22]

acute and delayed

a single 0.25 mg bolus given over 30 seconds at Â»30 minutes prior to chemotherapy

cinv (hec)[13,22]

acute

a single 0.25 mg bolus given over 30 seconds at Â»30 minutes prior to chemotherapy

ponv[13]

0â€“24 h

a single 0.075 mg bolus given over 10 seconds immediately before induction of anaesthesia

hec = highly emetogenic chemotherapy; mec = moderately emetogenic chemotherapy.

prolongation are unlikely to be caused by  xxxd2834xxx  administration.[60]
7. dosage and administration
intravenous  xxxd2834xxx  is widely recommended in adult patients for the prevention of
cinv and, in the us, for the prevention of
ponv;[13] the recommended usage of intravenous
 xxxd2834xxx  is presented in table v. although a
single 0.5 mg oral dose of oral  xxxd2834xxx  has
been approved for the prevention of acute phase
cinv in the us,[14] it is not currently available.
 xxxd2834xxx  should only be given to pregnant
patients if its use is considered essential by
the physician (pregnancy category b); the use of
 xxxd2834xxx  by nursing mothers should be
avoided.[13,14,22]
the local manufacturerâ€™s prescribing information should be consulted for detailed information
regarding contraindications, warnings, drug interactions, patient monitoring recommendations
and use in special patient populations.
8. place of  xxxd2834xxx  in the
prevention of nausea and vomiting
patients scheduled to receive chemotherapy or
to undergo surgery rank nausea and vomiting
among the top four treatment-related consequences that cause concern.[5,6] however, the
persistence of cinv[9] and ponv[10] despite the
numerous available agents and the use of combination prophylaxis (section 1) indicate that
cinv and ponv continue to be inadequately
controlled. a reduction in the incidence of cinv
and ponv would have significant benefits on
patient recovery and hr-qol,[61] as well as decreasing the financial burden in the management
of cancer or surgical patients.[4,11]
Âª 2009 adis data information bv. all rights reserved.

the management of cinv or ponv should
include identification of the risk factors (e.g. female sex, emetogenicity of the chemotherapy,
anaesthetic or analgesic agents, history of motion
sickness[2-4]) to help determine the most appropriate prophylactic regimen, which may range
from no prophylaxis or nonpharmacological intervention (e.g. p6 acupressure) in patients at low
risk to a combination of multiple antiemetic
agents in patients with higher risk.[4,11] recommendations from key treatment guidelines of
the use of pharmacological antiemetic agents for
cinv or ponv are presented in table vi.
since their introduction,  xxxg1116xxx  antagonists have been widely investigated and used
in cinv[3] or ponv[8] prevention and have become the cornerstone in the prevention of
cinv.[11] although  xxxg1116xxx  antagonists
are often recommended interchangeably (table vi),
resistance to one agent does not exclude the efficacy of another agent;[68] the pharmacological
differences between members of this class of
drugs (including  xxxd2834xxx ) and genetic
polymorphism may account for the lack of cross
resistance.[15]
key pharmacological properties of  xxxd2834xxx  distinguish it from the other  xxxg1116xxx 
antagonists.[69] these differences include a chemical structure that does not resemble serotonin
(and other  xxxg1116xxx  antagonists), a higher
affinity for the  xxxg1116xxx  than other 5-ht3
receptor antagonists, a long duration of action
(section 2) and a long half-life (section 3). but,
like other  xxxg1116xxx  antagonists in general,[70]  xxxd2834xxx  has a low risk of drug-drug
interactions (section 3), which may be of benefit
in patients scheduled to receive other drugs,
including chemotherapy or anaesthetic agents,
other antiemetic agents or treatments for concurrent disorders.
drugs 2009; 69 (16)

 xxxd2834xxx : a review

2273

table vi. summary of recommended treatment options for the pharmacological prevention of moderate- or high-risk chemotherapy-induced
nausea and vomiting (cinv) or postoperative nausea and vomiting (ponv) in adult patients, based on major guidelines. consult individual
guidelines for further details on risk definitions, recommended regimens and nonpharmacological prophylactic recommendations
indication (risk)

guideline

day 1

day 2 and onwards

cinv (moderate)

asco[62]

5-ht3 ra + dex + apra

dex (day 2, 3) â€“ apr (day 2, 3)a

esmo[63]

5-ht3 ra + corb + apra

corb or 5-ht3 ra or apra

mascc[64]

5-ht3 ra + dex + apr or fosc

cor or 5-ht3 ra or aprd

nccn[65]

5-ht3 ra + dex + apr or fos

dex or 5-ht3 raf,g

cinv (high)

ponv (moderate)
ponv (high)

[62]

5-ht3 ra + dex + apr

esmo[63]

5-ht3 ra + cor + apr

cor + apr

mascc[64]

5-ht3 ra + dex + apr or fos

dex + aprh

asco

dex (days 2â€“4) + apr (day 2, 3)

nccn[65]

5-ht3 rai + dex + apr or fosf

dex (day 2â€“4) + apr (days 2, 3) â€“ lor (days 2â€“4)

aspan[66]

one prophylactic interventionj

a drug that acts on another receptor sitek

samba[67]

combination of â€¡1 drug from >1 classl

aspan

[66]
[67]

samba
a

e,f

another class of drugsm
j

two or more prophylactic interventions

a drug that acts on another receptor sitek

combination of â€¡2 drugs from >1 class

l

another class of drugsm

apr is a recommended addition or alternative only in patients receiving an anthracycline and cyclophosphamide in combination.

b

dex is specifically recommended for patients receiving an anthracycline and cyclophosphamide in combination.

c

apr or fos is a recommended addition only in female patients receiving an anthracycline and cyclophosphamide in combination.

d

in patients who do did not receive apr on day 1, dex is the preferred option.

e

apr or fos is a recommended addition only in patients receiving chemotherapies such carboplatin, cisplatin, doxorubicin,  xxxd2008xxx ,
ifosfamide, irinotecan or methotrexate.

f

lor, and an  xxxg1079xxx  antagonist or a  xxxg215xxx  inhibitor, are recommended but optional additions.

g

apr â€“ dex is a recommended option only in patients who received apr on day 1.

h

this combination is recommended for patients who received cisplatin and 5-ht3 + dex + apr on day 1.

i

 xxxd2834xxx  is the preferred agent.

j

recommended agents include dex, 5-ht3 ra,  xxxg1078xxx  antagonist, sco patch or dro.

k

recommended agents include 5-ht3 ra,  xxxg1078xxx  antagonist, dro, low dose promethazine,  xxxd3018xxx  or metoclopramide.

l

recommended agents include 5-ht3, dex or dro.

m recommended agents include dex,  xxxd1945xxx  or promethazine, or a 5-ht3 ra for patients who did not receive prophylaxis.
5-ht3 ra = serotonin  xxxg1116xxx  antagonist; apr =  xxxd203xxx ; asco = american society of clinical oncology; aspan = american
society of perianesthesia nurses; cor = corticosteroid; dex = dexamethasone; dro =  xxxd1945xxx ; esmo = european society for medical
oncology; fos = fosaprepitant; lor = lorazepam; mascc = multinational association of supportive care in cancer; nccn = national
comprehensive cancer network; samba = society for ambulatory anesthesia; sco = scopolamine.

in adult patients (including the elderly),
intravenous  xxxd2834xxx  was shown to have
noninferior efficacy relative to intravenous ondansetron or intravenous  xxxd1924xxx  in preventing acute-phase cinv following mec (with
statistically better efficacy than ondansetron),
and to intravenous ondansetron or intravenous
granisetron in preventing acute-phase cinv following hec (section 4.1). importantly, intravenous  xxxd2834xxx  demonstrated statistically
better efficacy in terms of cr and cc rates in the
delayed phase than intravenous ondansetron or
 xxxd1924xxx  in mec trials (section 4.1.1).
Âª 2009 adis data information bv. all rights reserved.

current guidelines (table vi) typically recommend a combination of a  xxxg1116xxx 
antagonist with dexamethasone and  xxxd203xxx 
for cinv prevention, but the trials discussed in
section 4.1 did not always include dexamethasone
and only two trials[39,40] included  xxxd203xxx . the
three-drug combination has demonstrated good
efficacy in patients receiving mec (section 4.1.1)
or hec (section 4.1.2).
a recent meta-analyses (abstract presentation)[71]
reported statistically similar efficacy (in terms of cr
rates) between intravenous or oral  xxxd2834xxx 
0.25 mg and 0.75 mg (0.25 mg is the only approved
drugs 2009; 69 (16)

2274

intravenous dose and 0.50 mg is the only approved oral dose [section 7]). using data from
1926 patients enrolled in eight randomized, doubleblind clinical trials, the rr of cr rates between
 xxxd2834xxx  0.75 mg and 0.25 mg was 0.958â€“
1.102 in patients receiving mec or hec, for
acute emesis or delayed emesis (all p > 0.27).[71]
this similarity in efficacy between the two  xxxd2834xxx  doses was supported by another metaanalysis (abstract presentation) of data from
1947 patients.[72]
in light of the similar efficacy between  xxxd2834xxx  0.25 and 0.75 mg doses as suggested
by these meta-analyses,[71,72] results from a recent, large (n = 1114), randomized, double-blind,
double-dummy, multicentre, phase iii trial[50]
warrant discussion. in this trial, intravenous  xxxd2834xxx  0.75 mg plus dexamethasone 16 mg
was noninferior to intravenous granisetron
40 mg/kg plus dexamethasone 16 mg in the acute
phase in patients receiving hec (75.3% vs 73.3%;
95% ci for the between-group difference -2.70,
7.27) [co-primary endpoint].[50] in addition, a
statistically significant difference was reported
for the cr rate in the delayed phase between
the  xxxd2834xxx  and the granisetron groups
(56.8% vs 44.5%; 95% ci 6.39, 18.04; p < 0.0001)
[co-primary endpoint]. secondary endpoint findings (e.g. cc rates, patients with no nausea and
patients with no emetic episodes) were in support
of the co-primary endpoint findings. no clinically
relevant difference in the incidence of adverse
events were reported between the treatment
arms.[50]
the efficacy of  xxxd2834xxx  in preventing cinv
is further supported by a randomized, double-blind,
double-dummy, multicentre trial (abstract and poster presentation)[51] that compared intravenous  xxxd2834xxx  0.25 mg with subcutaneous granisetron
sustained release (apf530). although not an approved formulation, apf530 is designed to release
the granisetron over a 5-day period. in this trial,
noninferiority (achieved if the lower boundary of the
95% ci for the between-group difference was less
than -15%) was established between granisetron
5 mg (apf530 250 mg), 10 mg (apf530 500 mg)
and  xxxd2834xxx  0.25 mg in preventing cinv in the
Âª 2009 adis data information bv. all rights reserved.

yang & scott

acute, delayed and overall phases following mec or
hec (48.6â€“77.7%, 54.2â€“81.3% vs 52.4â€“80.7%).[51]
these additional efficacy findings[50,51,71,72]
have led to a recent national comprehensive
cancer network guideline[65] change, which specifies intravenous  xxxd2834xxx  as the preferred
 xxxg1116xxx  antagonist for the prevention of
cinv following hec (table vi). a change to the
multinational association for supportive care in
cancer and the european society for medical
oncology guidelines has recently been proposed,
to recommend  xxxd2834xxx  as the preferred
 xxxg1116xxx  antagonist in the prevention of
cinv following mec.[73]
although not currently approved for use in
paediatric patients (section 7), the use of intravenous  xxxd2834xxx  as cinv prophylaxis
has been investigated in two trials in paediatric
patients who received mec[74] or hec.[74,75]
oral  xxxd2834xxx  was noninferior to intravenous  xxxd2834xxx  in the prevention of
acute- and delayed-phase cinv in patients
receiving mec (section 4.1.1). as other 5-ht3
receptor antagonists are also available in oral
formulations,[62] comparative efficacy trials of oral
 xxxd2834xxx  with these drugs are warranted.
intravenous  xxxd2834xxx  was superior to
placebo in the prevention of ponv in the first
24 hours following surgery in two large noninferiority trials,[36,37] but the efficacy of  xxxd2834xxx  was statistically greater than placebo in the
24â€“72 hour time period in only one[37] of these
trials (section 4.2). interestingly, other  xxxg1116xxx  antagonists also demonstrate better efficacy during the early than the later phase of
ponv.[8] comparative studies between  xxxd2834xxx  and other  xxxg1116xxx  antagonists
would be beneficial in fully determining the relative position of these agents for the prophylaxis
of ponv.
hr-qol results from clinical studies generally support the use of intravenous  xxxd2834xxx  over that of ondansetron or  xxxd1924xxx 
in preventing cinv in patients receiving mec,
and of ondansetron in patients receiving hec
(section 4.1). intravenous  xxxd2834xxx  was
associated with better patient functioning than
placebo when given as ponv prophylaxis
drugs 2009; 69 (16)

 xxxd2834xxx : a review

(section 4.2). additional studies of the effect of
oral  xxxd2834xxx  compared with other oral
 xxxg1116xxx  antagonists as cinv prophylaxis, or of intravenous  xxxd2834xxx  and other
intravenous  xxxg1116xxx  antagonists in
ponv prophylaxis, would be of interest.
in addition to the clinical benefits associated
with cinv prophylaxis, there are also financial
benefits. based on data from 20 community oncology practices, the cost of managing an extreme
cinv event (i.e. failed cinv prophylaxis) was
estimated to be $us175 (2005 values), requiring
255 minutes of an advanced practice nurse or a
physicianâ€™s time.[76] results from two european
cost models and a retrospective analysis of a us
medical database indicate pharmacoeconomic
advantages associated with the use of  xxxd2834xxx  over that of ondansetron or other 5-ht3
receptor antagonists as cinv prophylaxis (section 5). however, input data (e.g. those for
hr-qol) are limited in the two modelled studies,[57,58] and affect the robustness of the pharmacoeconomic estimates. it would be of interest
for future pharmacoeconomic models to compare both the efficacy and acquisition-cost ratios
of  xxxd2834xxx  with that of other 5-ht3
receptor antagonists. in addition, pharmacoeconomic studies comparing intravenous  xxxd2834xxx  with other  xxxg1116xxx  antagonists in
ponv prophylaxis are needed.
like other  xxxg1116xxx  antagonists,[3,11,69]
 xxxd2834xxx  was associated with a good tolerability profile in clinical trials. the most commonly reported adverse events, mostly of mild to
moderate severity, following administration of
 xxxd2834xxx  include headache and constipation
(section 6), which are typical of all  xxxg1116xxx  antagonists.[11] importantly,  xxxd2834xxx 
is not associated with qtc interval prolongation
(section 6) or other adverse cardiac effects (section 2), which is of clinical advantage as some
chemotherapy agents (e.g. cisplatin,  xxxd226xxx [77]) or anaesthetic drugs (e.g.  xxxd3197xxx ,
sufentanil[78]) may prolong the qtc interval or
cause arrhythmias.
in conclusion, in large, double-blind trials, intravenous  xxxd2834xxx  was noninferior to intravenous
ondansetron (with statistically greater efficacy than
Âª 2009 adis data information bv. all rights reserved.

2275

ondansetron) or intravenous  xxxd1924xxx  in preventing acute- and delayed-phase cinv associated with
mec, and to intravenous ondansetron or granisetron in preventing acute-phase cinv associated
with hec. the oral formulation of  xxxd2834xxx 
was noninferior to the intravenous formulation as
prophylactic treatment for acute-phase cinv in
patients receiving mec in another large, double
blind-trial. intravenous  xxxd2834xxx  was superior
to placebo in preventing ponv in the first 24 hours
following surgery in two large, double-blind trials.
 xxxd2834xxx  was generally well tolerated in participants in clinical trials. intravenous  xxxd2834xxx  is
a valuable option in the prevention of acute- and
delayed-phase cinv in adult patients receiving
mec, and of acute-phase cinv in patients receiving hec. oral  xxxd2834xxx  is likely to be a useful
alternative to existing oral formulations of 5-ht3
receptor antagonists in preventing cinv in patients receiving mec, as is intravenous  xxxd2834xxx  to currently recommended agents in ponv
prevention.
disclosure
the preparation of this review was not supported by any
external funding. during the peer review process, the manufacturer of the agent under review was offered an opportunity
to comment on this article. changes resulting from comments
received were made on the basis of scientific and editorial merit.

references
1. kovac al. benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.
drug saf 2003; 26 (4): 227-59
2. apfel cc, laÌˆaÌˆraÌˆ e, koivuranta m, et al. a simplified risk
score for predicting postoperative nausea and vomiting:
conclusions from cross-validations between two centers.
anesthesiology 1999 sep; 91 (3): 693-700
3. lohr l. chemotherapy-induced nausea and vomiting.
cancer j 2008 mar-apr; 14 (2): 85-93
4. kovac al. prevention and treatment of postoperative
nausea and vomiting. drugs 2000; 59 (2): 213-43
5. de boer-dennert m, de wit r, schmitz pim, et al. patient
perceptions of the side-effects of chemotherapy: the influence
of 5ht3 antagonists. br j cancer 1997; 76 (8): 1055-61
6. jenkins k, grady d, wong j, et al. post-operative recovery:
day surgery patientsâ€™ preferences. br j anaesth 2001 feb;
86 (2): 272-4
7. stieler jm, reichardt p, riess h, et al. treatment options
for chemotherapy-induced nausea and vomiting: current
and future. am j cancer 2003; 2 (1): 15-26

drugs 2009; 69 (16)

yang & scott

2276

8. gan tj. mechanisms underlying postoperative nausea and
vomiting and neurotransmitter receptor antagonist-based
pharmacotherapy. cns drugs 2007; 21 (10): 813-33
9. hickok jt, roscoe ja, morrow gr, et al. nausea and
emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics:
a university of rochester james p. wilmot cancer center
community clinical oncology program study of 360 cancer patients treated in the community. cancer 2003 jun 1;
97 (11): 2880-6
10. gupta a, wu cl, elkassabany n, et al. does the routine
prophylactic use of antiemetics affect the incidence of
postdischarge nausea and vomiting following ambulatory
surgery? a systematic review of randomized controlled
trials. anesthesiology 2003 aug; 99 (2): 488-95
11. hesketh pj. chemotherpy-induced nausea and vomiting.
n engl j med 2008 jun 5; 358 (23): 2482-94
12. siddiqui ma, scott lj.  xxxd2834xxx . drugs 2004; 64 (10):
1125-32; discussion 1133-4
13. us fda.  xxxd2834xxx  ( xxxd2834xxx  hydrochloride) injection for
intravenous use: us prescribing information [online]. available from url: http://www.accessdata.fda.gov/drugsatfda_
docs/label/2008/021372s008s010lbl.pdf [accessed 2009 jul 28]
14. us fda.  xxxd2834xxx  ( xxxd2834xxx  hydrochloride) capsules:
us prescribing information [online]. available from url:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/
022233lbl.pdf [accessed 2009 jul 28]
15. ho k-y, gan tj. pharmacology, pharmacogenetics, and
clinical efficacy of 5-hydroxytryptamine type 3 receptor
antagonists for postoperative nausea and vomiting. curr
opin anaesthesiol 2006 dec; 19 (6): 606-11
16. rojas c, grunberg s, rosti g. creating real benefit for
patients at risk of nausea and vomiting:  xxxd2834xxx  from
bench to bedside. clin adv hematol oncol 2007 dec; 5
(12 suppl. 19): 4-17
17. rojas c, stathis m, thomas ag, et al.  xxxd2834xxx  exhibits unique molecular interactions with the 5-ht3
receptor [published erratum appears in anesth analg
2008 oct; 107 (4): 1405]. anesth analg 2008 aug; 107 (2):
469-78
18.  xxxd1704xxx  rm, lee c-h, smith wl, et al. pharmacological
characterization of rs 25259-197, a novel and selective
 xxxg1116xxx  antagonist, in vivo. br j pharmacol 1995
feb; 114 (4): 860-6
19. lorusso v, spedicato a, petrucelli l, et al. single dose of
 xxxd2834xxx  plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients
treated with highly emetogenic chemotherapy (hec). preliminary results. support care cancer. epub 2009 mar 18
20. wong ehf, clark r, leung e, et al. the interaction of
rs 25259-197, a potent and selective antagonist, with
5-ht3 receptors, in vitro. br j pharmacol 1995 feb; 114 (4):
851-9
21. morganroth j, parisi s, moresino c, et al. high dose  xxxd2834xxx  does not alter ecg parameters including qtc
interval in healthy subjects: results of a dose-response,
double blind, randomized, parallel e14 study of  xxxd2834xxx  vs. moxifloxacin or placebo [abstract no. 1156]. ejc
supplements 2007 sep; 5 (4): 158-9
22. european medicines agency.  xxxd2834xxx  ( xxxd2834xxx ) 250 mg
solution for injection: summary of product characteristics

Âª 2009 adis data information bv. all rights reserved.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

[online]. available from url: http://www.emea.europa.
eu/humandocs/pdfs/epar/ xxxd2834xxx /h-563-pi-en.pdf [accessed 2009 mar 23]
european medicines agency. european public assessment
report for  xxxd2834xxx  ( xxxd2834xxx ): scientific discussion [online]. available from url: http://www.emea.europa.eu/
humandocs/pdfs/epar/ xxxd2834xxx /056305en6.pdf [accessed
2008 nov 13]
international conference on harmonisation of technical
requirements for registration of pharmaceuticals for
human use. the clinical evaluation of qt/qtc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs: e14 [online]. available from url:
http://www.ich.org/lob/media/media1476.pdf [accessed
2009 apr 6]
stoltz r, cyong j-c, shah a, et al. pharmacokinetic and
safety evaluation of  xxxd2834xxx , a 5-hydroxytryptamine3 receptor antagonist, in u.s. and japanese healthy subjects. j clin pharmacol 2004 may; 44 (5): 520-31
hunt tl, gallagher sc, cullen mt, et al. evaluation of
safety and pharmacokinetics of consecutive multiple-day
dosing of  xxxd2834xxx  in healthy patients. j clin pharmacol 2005 may; 45 (5): 589-96
einhorn lh, brames mj, dreicer r, et al.  xxxd2834xxx  plus
dexamethasone for prevention of chemotherapy-induced
nausea and vomiting in patients receiving multiple-day
cisplatin chemotherapy for germ cell cancer. support care
cancer 2007 nov; 15 (11): 1293-300
stoltz r, parisi s, shah a, et al. pharmacokinetics, metabolism and excretion of intravenous [14c]- xxxd2834xxx  in
healthy human volunteers. biopharm drug dispos 2004
nov; 25 (8): 329-37
shah ak, hunt tl, gallagher sc, et al. pharmacokinetics
of  xxxd2834xxx  in combination with  xxxd203xxx  in healthy
volunteers. curr med res opin 2005 apr; 21 (4): 595-601
eisenberg p, mackintosh fr, ritch p, et al. efficacy,
safety and pharmacokinetics of  xxxd2834xxx  in patients
receiving highly emetogenic cisplatin-based chemotherapy:
a dose-ranging clinical study. ann oncol 2004 feb; 15 (2):
330-7
eisenberg p, figueroa-vadillo j, zamora r, et al. improved
prevention of moderately emetogenic chemotherapyinduced nausea and vomiting with  xxxd2834xxx , a pharmacologically novel  xxxg1116xxx  antagonist: results of a
phase iii, single-dose trial versus  xxxd1924xxx . cancer 2003
dec 1; 98 (11): 2473-82
gralla r, lichinitser m, van der vegt s, et al.  xxxd2834xxx 
improves prevention of chemotherapy-induced nausea and
vomiting following moderately emetogenic chemotherapy:
results of a double-blind randomized phase iii trial comparing single doses of  xxxd2834xxx  with ondansetron. ann
oncol 2003 oct; 14 (10): 1570-7
aapro ms, grunberg sm, manikhas gm, et al. a phase iii,
double-blind, randomized trial of  xxxd2834xxx  compared
with ondansetron in preventing chemotherapy-induced
nausea and vomiting following highly emetogenic chemotherapy. ann oncol 2006 sep; 17 (9): 1441-9
yu z, liu w, wang l, et al. the efficacy and safety of
 xxxd2834xxx  compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting
in the chinese cancer patients: a phase ii, multicenter,

drugs 2009; 69 (16)

 xxxd2834xxx : a review

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

randomized, double-blind, parallel, comparative clinical
trial. support care cancer 2009 jan; 17 (1): 99-102
grunberg s, voisin d, zufferli m, et al. oral  xxxd2834xxx 
(palo) is as effective as intravenous (iv) palo: a phase 3
dose ranging trial in patients (pts) receiving moderately
emetogenic chemotherapy (mec) [abstract no. 1143]. ejc
supplements 2007 sep 4; 5: 155. plus poster presented at
the 14th european conference of clinical oncology; 2007
sep 23-27; barcelona
candiotti ka, kovac al, melson ti, et al. a randomized,
double-blind study to evaluate the efficacy and safety of
three different doses of  xxxd2834xxx  versus placebo for
preventing postoperative nausea and vomiting. anesth
analg 2008 aug; 107 (2): 445-51
kovac al, eberhart l, kotarski j, et al. a randomized,
double-blind study to evaluate the efficacy and safety
of three different doses of  xxxd2834xxx  versus placebo
in preventing postoperative nausea and vomiting over a
72-hour period. anesth analg 2008 aug; 107 (2): 439-44
white pf, scuderi p. prevention of postoperative nausea
and vomiting (ponv): a dose-ranging study involving
 xxxd2834xxx , a potent  xxxg1116xxx  antagonist [abstract
no. a703]. anesthesiology 2005 oct; 103: ea703
grote t, hajdenberg j, cartmell a, et al. combination
therapy for chemotherapy-induced nausea and vomiting in
patients receiving moderately emetogenic chemotherapy:
 xxxd2834xxx , dexamethasone, and  xxxd203xxx . j support
oncol 2006 sep; 4 (8): 403-8
herrington jd, jaskiewicz ad, song j. randomized,
placebo-controlled, pilot study evaluating  xxxd203xxx  single
dose plus  xxxd2834xxx  and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. cancer 2008 may 1; 112 (9): 2080-7
massa e, astara g, madeddu c, et al.  xxxd2834xxx  plus
dexamethasone effectively prevents acute and delayed
chemotherapy-induced nausea and vomiting following
highly or moderately emetogenic chemotherapy in pretreated patients who have failed to respond to a previous
antiemetic treatment: comparison between elderly and
non-elderly patient response. crit rev oncol hematol
2009 apr; 70 (1): 83-91
fabi a, noleâ€™ f, roila f, et al. comparison of  xxxd2834xxx 
(palo) plus dexamethasone on day 1, with or without dexamethasone on days 2 and 3, in the prevention of
chemotherapy induced nausea and vomiting (cinv) in
breast cancer patients treated with anthracycline/
cyclophosphamide regimens [abstract no. 4088]. 31st
annual san antonio breast cancer symposium; 2008 dec
10-14; san antonio (tx)
clark o, engel t, clark l, et al. efficacy of  xxxd2834xxx 
(pal) compared to other serotonin inhibitors ( xxxg1116xxx ) in
preventing chemotherapy-induced nausea and vomiting
(cinv) in patients receiving moderately or highly emetogenic (mohe) treatments: systematic review and metaanalysis [abstract no. e20620]. j clin oncol 2009 may;
27 (15 suppl.): e20620
petru e, andel j, angleitner-boubenizek l, et al. early
austrian multicenter experience with  xxxd2834xxx  as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. wien med wochenschr
2008; 158 (5-6): 169-73

Âª 2009 adis data information bv. all rights reserved.

2277

45. aapro ms, macciocchi a, gridelli c.  xxxd2834xxx  improves prevention of chemotherapy-induced nausea and
vomiting in elderly patients. j support oncol 2005 sep-oct;
3 (5): 369-74
46. martin ar, pearson jd, cai b, et al. assessing the impact of
chemotherapy-induced nausea and vomiting on patientsâ€™
daily lives: a modified version of the functional living
index-emesis (flie) with 5-day recall. support care
cancer 2003 aug; 11 (8): 522-7
47. lindley cm, hirsch jd, oâ€™neill cv, et al. quality of life
consequences of chemotherapy-induced emesis. qual life
res 1992 oct; 1 (5): 331-40
48. decker gm, demeyer es, kisko dl. measuring the
maintenance of daily life activities using the functional
living index-emesis (flie) in patients receiving moderately emetogenic chemotherapy. j support oncol 2006 jan;
4 (1): 35-41, 52
49. boccia rv, gonzalez ef, pluzanska ag, et al.  xxxd2834xxx  (palo), administered orally or intravenously (iv),
plus dexamethasone for prevention of chemotherapyinduced nausea and vomiting (cinv) [abstract no. 20608].
j clin oncol 2008 may 20; 26 (15 suppl. pt i): e20608
50. saito m, aogi k, sekine i, et al.  xxxd2834xxx  plus dexamethasone versus granisetron plus dexamethasone for
prevention of nausea and vomiting during chemotherapy: a
double-blind, double-dummy, randomised, comparative
phase iii trial. lancet oncol 2009 feb; 10 (2): 115-24
51. grous jj, riegel e, gabrail n, et al. phase iii study of
sustained release granisetron (apf530) compared to  xxxd2834xxx  for the prevention of chemotherapy-induced
nausea and vomiting (cinv) [abstract no. 9627]. j clin
oncol 2009 may; 27 (15 suppl.): 514s. plus poster presented at the annual meeting of the american society of
clinical oncology; 2009 may 29-jun 2; orlando (fl)
52. celio l, bajetta e, denaro a, et al. single-day regimen of
 xxxd2834xxx  (palo) and dexamethasone (dex) for the
prevention of emesis associated with moderately emetogenic chemotherapy (mec): subgroup analysis from a
randomized phase iii trial [abstract no. 9620]. j clin oncol
2009 may; 27 (15 suppl.): 513s
53. american society of anesthesiologists. asa physical status
classification system [online]. available from url: http://
www.asahq.org/clinical/physicalstatus.htm [accessed 2008
dec 12]
54. tang j, dâ€™angelo r, white pf, et al. the efficacy of rs25259, a long-acting selective  xxxg1116xxx  antagonist, for
preventing postoperative nausea and vomiting after hysterectomy procedures. anesth analg 1998 aug; 87: 462-7
55. aaronson nk, ahmedzai s, bergman b, et al. the european organization for research and treatment of cancer
qlq-c30: a quality-of-life instrument for use in international clinical trials in oncology. j natl cancer inst 1993
mar 3; 85 (5): 365-76
56. osoba d, zee b, pater j, et al. psychometric properties and
responsiveness of the eortc quality of life questionnaire (qlq-c30) in patients with breast, ovarian and
lung cancer. qual life res 1994 oct; 3 (5): 353-64
57. tarricone r, girolami f. economic evaluation of a nw antiemetic drug:  xxxd2834xxx  versus ondansetron; assessment of the drug price ratio in five european countries.
clin drug investig 2005; 25 (9): 597-608

drugs 2009; 69 (16)

yang & scott

2278

58. ravasio r, lucioni c. economic evaluation of prevention
of chemotherapy-induced nausea and vomiting (cinv):
 xxxd2834xxx  versus first generation  xxxg1116xxx  antagonists [in italian]. pharmacoeconomics ital res articles
2007; 9 (1): 21-30
59. feinberg ba, gilmore j, haislip s, et al. data-driven
medical decision-making in managing chemotherapyinduced nausea and vomiting. comm oncol 2009 feb;
6 (2): 62-7
60. kovac a, clerici g, schernikau u, et al.  xxxd2834xxx , a
novel 5ht3 antagonist, does not prolong qtc interval in
patients undergoing surgery [abstract no. a287]. anesthesiology 2007; 107: ea287
61. bloechl-daum b, deuson rr, mavros p, et al. delayed
nausea and vomiting continue to reduce patientsâ€™ quality of
life after highly and moderately emetogenic chemotherapy
despite antiemetic treatment. j clin oncol 2006 sep 20;
24 (27): 4472-8
62. kris mg, hesketh pj, somerfield mr, et al. american
society of clinical oncology guideline for antiemetics in
oncology: update 2006. american society of clinical
oncology [published erratum appears in j clin oncol 2006
nov 20; 24 (33): 5341-2]. j clin oncol 2006 jun 20; 24 (18):
2932-47
63. herrstedt j, roila f, esmo guidelines working group.
chemotherapy-induced nausea and vomiting: esmo
clinical recommendations for prophylaxis. ann oncol 2009
may; 20 suppl. 4: 156-8
64. multinational association of supportive care in cancer.
perugia international cancer conference vii: antiemetic guidelines (march 2008) [online]. available from
url:
http://www.mascc.org/media/resource_centers/
mascc_guidelines_update.ppt [accessed 2009 may 25]
65. national comprehensive cancer network. nccn clinical
practice guidelines in oncology: antiemesis (v.4.2009)
[online]. available from url: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
[accessed
2009 sep 17]
66. american society of perianesthesia nurses ponv/pdnv
strategic work team. aspanâ€™s evidence-based clinical
practice guideline for the prevention and/or management of ponv/pdnv. j perianesth nurs 2006 aug; 21 (4):
230-50
67. gan tj, meyer ta, apfel cc, et al. society for ambulatory
anesthesia guidelines for the management of postoperative
nausea and vomiting. anesth analg 2007 dec; 105 (6):
1615-28
68. de wit r, de boer ac, vd linden ghm, et al. effective
cross-over to granisetron after failure to ondansetron, a
randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours fol-

Âª 2009 adis data information bv. all rights reserved.

69.

70.

71.

72.

73.

74.

75.

76.

77.
78.

lowing highly emetogenic chemotherapy. br j cancer 2001
oct 19; 85 (8): 1099-101
navari rm. pharmacological management of chemotherinduced nausea and vomiting: focus on recent developments. drugs 2009; 69 (5): 515-33
gan tj. selective serotonin  xxxg1116xxx  antagonists for
postoperative nausea and vomiting: are the all the same?
cns drugs 2005; 19 (3): 225-38
raftopoulos h, bria e, gralla r, et al. is there a preferred
dose of  xxxd2834xxx ? results of an abstracted data (ad)
meta-analysis (ma) of all eight randomized double-blind
(rdb) studies and the impact on guideline considerations
[abstract no. 9636]. j clin oncol 2009 may; 27 (15 suppl.):
517s. plus poster presented at the annual meeting of the
american society of clinical oncology; 2009 may 29-jun
2; orlando (fl)
lesser m, gralla r, napolitano b, et al. determining the
preferred dose of the serotonin antagonist (5-ht3)  xxxd2834xxx : results of an individualized patient data metaanalysis (ma) of 1,947 patients in all randomized double
blind (rdb) trials [abstract no. e20512]. j clin oncol 2009
may; 27 (15 suppl.): e20512
mascc antiemetic study group. mascc/esmo comittees ii-iv combined statement #3: moderate [slide presentation]. mascc/isoo annual symposium; 2009 jun
27; rome
kadota r, shen v, messinger y. safety, pharmacokinetics,
and efficacy of  xxxd2834xxx  in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized
study [abstract no. 9570]. j clin oncol 2007 jun 20; 25
suppl. 18: 543
sepuÌlveda-vildoÌsola ac, betanzos-cabrera y, lastiri gg,
et al.  xxxd2834xxx  hydrochloride is an effective and safe
option to prevent chemotherapy-induced nausea and vomiting in children. arch med res 2008 aug; 39 (6): 601-6
vanscoy gj, fortner b, smith r, et al. preventing chemotherapy-induced nausea and vomiting: the economic
implications of choosing antiemetics. commu oncol 2005
mar-apr; 2 (2): 127-32
floyd jd, nguyen dt, lobins rl, et al. cardiotoxicity of
cancer therapy. j clin oncol 2005 oct 20; 23 (30): 7685-96
de ponti f, poluzzi e, cavalli a, et al. safety of nonantiarrhythmic drugs that prolong the qt interval or induce torsage de pointes: an overview. drug saf 2002; 25 (4):
263-86

correspondence: lily p.h. yang, adis, a wolters kluwer
business, 41 centorian drive, private bag 65901, mairangi
bay, north shore 0754, auckland, new zealand.
e-mail: demail@adis.co.nz

drugs 2009; 69 (16)

